Exelixis, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EXEL research report →
About the company
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer.
- CEO
- Michael Morrissey
- IPO
- 2000
- Employees
- 1,147
- HQ
- Alameda, CA, US
Price Chart
- Market Cap
- $14.04B
- P/E
- 17.90
- P/S
- 5.91
- P/B
- 7.45
- EV/EBITDA
- 13.77
- Div Yield
- 0.00%
- Gross Margin
- 96.44%
- Op Margin
- 39.43%
- Net Margin
- 35.08%
- ROE
- 40.21%
- ROIC
- 35.01%
- Revenue
- $2.32B · 6.98%
- Net Income
- $782.57M · 50.13%
- EPS
- $2.88 · 60.00%
- Op Income
- $872.19M
- FCF YoY
- 33.22%
- 52W High
- $56.21
- 52W Low
- $33.76
- 50D MA
- $50.10
- 200D MA
- $44.18
- Beta
- 0.42
- Avg Volume
- 2.69M
Get TickerSpark's AI analysis on EXEL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 1, 26 | WYSZOMIERSKI JACK L | sell | 3,925 |
| Jun 1, 26 | Eckhardt Sue Gail | sell | 9,812 |
| May 27, 26 | PAPADOPOULOS STELIOS | other | 8,367 |
| May 27, 26 | Heyman Tomas J. | other | 8,367 |
| May 27, 26 | Eckhardt Sue Gail | other | 8,367 |
| May 27, 26 | Smith Julie | other | 8,367 |
| May 27, 26 | Freire Maria C | other | 8,367 |
| May 27, 26 | Beckerle Mary C | other | 8,367 |
| May 27, 26 | Oliver Bob | other | 8,367 |
| May 27, 26 | WYSZOMIERSKI JACK L | other | 8,367 |
Our EXEL coverage
Recent articles, reports, and earnings notes.
No research on EXEL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EXEL report →Similar companies
Peers in the same neighborhood.